Revised cell therapy for recurrent brain cancer
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain cancer called glioblastoma that has returned or progressed.
- You are between 18 and 70 years old.
- Your tumor tissue has at least 1% of cells with CD44 or CD133 markers (for the second phase of the trial).
- You have at least one measurable tumor that is no larger than 3 cm across.
- You have had prior treatment with radiation, temozolomide, or bevacizumab.
- You are healthy enough for a procedure to place a small reservoir (Ommaya) under your scalp for drug delivery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This Phase 1 study tests an “allogenic” stem cell product made from donated fat tissue to treat recurrent glioblastoma or certain recurrent astrocytoma. It gives the treatment around the time of a repeat brain surgery, and focuses on safety while also studying why it might help.
This trial tests a new CAR-T cell therapy for people recently diagnosed with glioblastoma, a type of brain cancer. It uses the patient's own immune cells, modified to target markers on the tumor. The goal is to see if this treatment can help control the cancer after surgery and before standard therapies like radiation or chemotherapy.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new kind of cell therapy called CAR-T, made from donor cells, to treat glioblastoma that has come back. The treatment targets a specific marker on the tumor (B7H3) and is injected into the brain to attack the cancer cells.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.